Экспрессия белков, регулирующих апоптоз, на лейкозных клетках разных этапов В-клеточной дифференцировки тема диссертации и автореферата по ВАК РФ 14.00.14, кандидат биологических наук Лысюк, Елена Юрьевна

• Лысюк, Елена Юрьевна
• кандидат биологических наук
• 2004

Оглавление диссертации кандидат биологических наук Лысюк, Елена Юрьевна

Содержание.

Список сокращений. введение.

Введение диссертации (часть автореферата) на тему «Экспрессия белков, регулирующих апоптоз, на лейкозных клетках разных этапов В-клеточной дифференцировки»

Цель работы.6

Задачи исследования.6

Научная новизна.6

Научно-практическая значимость.7

ЧАСТЬ I. ОБЗОР ЛИТЕРАТУРЫ.8

Заключение диссертации по теме «Онкология», Лысюк, Елена Юрьевна

Выводы.

1. Экспрессия Bcl-2 изменяется на этапах дифференцировки В-клеток.

2. Bcl-2 экспрессируется на стадии зрелых периферических В-клеток и отсутствует в ранних В-клетках, активированных В-клетках и плазматических клетках.

3. Вах экспрессируется в на стадии зрелых периферических В-клеток и отсутствует в активированных В-клетках и в клетках зародышевых центров лимфоузлов.

4. Высокая экспрессия CD95 наблюдается в рециркулирующих зрелых В-клетках, в клетках зародышевых центров лимфоузлов и в плазматических клетках.

5. Существует зависимость уровня экспрессии Bcl-2 от цитологического типа фолликулярной лимфомы и диффузно-крупноклеточной лимфомы. При I цитологическом типе фолликулярной лимфомы выявляется большое количество Bcl-2 положительных клеток, число которых достоверно снижается во II и III цитологических типах.

6. При хроническом лимфолейкозе наблюдается высокая экспрессия Bcl-2. Высокий уровень экспрессии белка сохраняется при отсутствии клипико-гематологической ремиссии, и достоверно снижается в случае достижения ремиссии.

7. Соотношение Bcl-2/Bax у больных хроническим лимфолейкозом снижается при достижении ремиссии. До лечения, а также при отсутствии ответа на лечение, значение соотношения повышено.

Список литературы диссертационного исследования кандидат биологических наук Лысюк, Елена Юрьевна, 2004 год

1. Барышников А.Ю., Сыркин А.Б., Полосухина Е.Р., Шишкин Ю.В., Гаврикова Н.В., Тупицын Н.Н., Андреева Л.Ю., Заботина Т.Н., Маякова С.А., Курмашов В.И., Кадагидзе З.Г. // Российский онкологический журнал, 1998, №4, 31-35.

2. Барышников А.Ю. и Шишкин Ю.В. / Fas/Apo-1 -антиген молекула, опосредующая апоптоз. // Гематология и трансфузиология, 1995, т.40, №6, 35-38.

3. Барышников А.Ю. и Шишкин Ю.В. / Программированная клеточная смерть (апоптоз). // Российский Онкологический журнал, 1996, №1, 58-61.

4. Глузман Д.Ф., Абраменко И.В., Скляренко Л.М., Надгорная В.А. / Лабораторная диагностика онкогематологических заболеваний. // Киев: Морион, 1998.

5. Ройт А., Бростофф Дж., Мейл Д. / Иммунология. Пер. с англ. // М.: Мир, 2000. 592 е., ил.

6. Тупицын Н.Н. / Иммунодиагностика лимфом. // Материалы 1-ой Российской конференции по онкогематологии «Злокачественые лимфомы». Москва, 2002.

7. Ярилин А.А. / Апоптоз и его место в иммунных процессах. // 1996, 10-23.

8. Adams J.M. and Cory S. / The Bcl-2 protein family: arbiters of cell survival. // Science, 1998, v.281, No.5381, 1322-1326.

9. Aguilar-Santelises M., Rottenberg M.E., Levvin N., Mellstedt H., Jondal M. / Bcl-2, Bax and p53 expression in B-CLL in relation to in vitro survival and clinical progression. // Int J Cancer, 1996, v.69, No.2, 114-119.

10. Arcinas M., Heckman C.A., Mehew J.W., Boxer L.M. / Molecular Mechanisms of Transcriptional Control of bcl-2 and c-myc in Follicular and Transfonned Lymphoma. // Cancer Research, 2001, v.61, 5202-5206.

11. Ashkenazi A. and Dixit V.M. / Death receptors: Signaling and modulation. // Science, 1998, v.281, No.5381, 1305-1308.

12. Bairey O., Ziinra Y., Shaklai M., Окоп E., Rabizadeh E. / Bcl-2, Bcl-x, Bax, and Bak expression in short- and long-lived patients with diffuse large B-cell lymphomas. // Clinical Cancer Research, 1999, v.5, 2860-2866.

13. Borner C. / Diminished cell proliferation associated with the death-protective activity of Bcl-2.//J Biol Chem, 1996, v.271,No.22, 12695-12698.

14. Capello D., Gaidano G. / Molecular pathophysiology of indolent lymphoma. // Haematologica, 2000, v.85, No.2, 195-201.

15. Chao D.T. and Korsmeyer S.J. / Bcl-2 family: regulators of cell death. // Annu. Rev. Immunol., 1998, v.16, 395-419.

16. Chauncey T.R. / Drug resistance mechanisms in acute leukemia. // Current Opinion in Oncology, 2001, v.13, 21-26.

17. Chinnaiyan A.M., O'Rourke K., Tewari M., Dixit V.M. / FADD, a novel deatli domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. // Cell, 1995, v.81, No.4, 505-512.

18. Chylicki K., Ehinger M., Sveberg H., Gullberg U. / Characterization of the molecular mechanisms for p53-mediated differentiation. // Cell Growth and Differentiation, 2000, v. 11, 561-571.

19. Coffman F.D. and Studzinski G.P. / Differentiation-related mechanisms which suppress DNA replication. // Experimental Cell Research, 1999, v.248, 58-73.

20. Coustan-Smith E., Kitanaka A., Pui C.-H., McNinch L., Evans W.E., Raimondi S.C., Behm F.G., Arico M., Campana D. / Clinical relevance of Bcl-2 overexpression in childhood acute lymphoblastic leukemia. // Blood, 1996, v.87, No.3, 1140-1146.

21. DaIIa-Favera R., Yc B.H., Lo Coco F., Gaidano G., Lista F., Knovvies D.M., Louie D.C., Offit K., Chaganti R.S. / Identification of genetic lesions associated with diffuse large-cell lymphoma. //Ann Oncol, 1994, v.5, Suppl.l, 55-60.

22. Donehovver L.A. / Tumor suppressor gene p53 and apoptosis. // The Cancer Bulletin, 1994, v.46, No.2, 161-166. .

23. Evan G. and Littlevvood T. / A matter of life and cell death. // Science, 1998, v.281, 1317-1322.

24. Еупоп E.E., Livak F., Kuida K., Schatz D.G., Flavell R.A. / Distinct effects of Jak3 signaling on ap and y8 thymocyte development. // The Journal of Immunology, 1999. v.162, 1448-1459.

25. Fisher D.E. / Apoptosis in cancer therapy: crossing the threshold. // Cell, 1994, v.78, 539-542.

26. Froelich C.J., Dixit V.M., Yang X. / Lymphocyte granule-mediated apoptosis: matters of viral mimicry and deadly proteases. / Immunology Today, 1998, v. 19, No. 1,30-36.

27. Green D.R. and Reed J.C. / Mitochondria and apoptosis. // Science, 1998, v.281, No.5381, 1309-1312.

28. Greenblatt M.S., Bennett W.P., Hollstein M., Harris C.C. / Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. // Cancer Research, 1994, v.54, No.l8, 4855-4878.

29. Gruss H.J., Dower S.K. / Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas. // Blood, 1995, v.85, No. 12, 33783404.

30. Hale A.J., Smith C.A., Sutherland L.C., Stoneman V.E.A., Longthorne V.L., Culhane A.C., Williams, G.T. / Apoptosis: molecular regulation of cell death. // Eur J Biochem, 1996, v.236, 1-26.

31. Hengartner M.O. / Death cycle and Swiss army knives. // Nature, 1998, v.391, 441-442.

32. Hirsch Т., Marzo I., Kroemer, G. / Role of the Mitochondrial Permeability Transition Pore in Apoptosis. // Bioscience Reports, 1997, v. 17, No.l, 67h-76.

33. Hockenbery D.M., Oltvai Z.N., Yin X.-M., Milliman C.L., Korsmeyer S.J. / Bcl-2 functions in an antioxidant pathway to prevent apoptosis. // Cell, 1993, v.75, 241251.

34. Hsu Y.-T., Wolter K.G., Youle R.J. / Cytosol-to-membrane redistribution of Bax and Bcl-xL during apoptosis. // Proc. Natl. Acad. Sci. USA, 1997, v.94, 36683672

35. Hu Y., Benedict М.Л., Wu D., Inohara N., Nunez G. / Bcl-xL interacts with Apaf-1 and inhibits Apaf-1-dependent caspase-9 activation. // Proc. Natl. Acad. Sci. USA, 1998, v.95, 4386-4391.

36. Huang D.C.S., Adams J.M., Cory S. / The conserved N-terminal BH4 domain of Bcl-2 homologous is essential for inhibition of apoptosis and interaction with CED-4. // The EMBO Journal, 1998, v. 17, No.4, 1029-1039.

37. Jaffe E., Harris N., Vardman J. / WHO classification of tumors. Tumors of Haematopoietic and Lymphoid Tissues. // Lion, 2001.

38. Jennings C.D. and Foon K.A. / Recent Advances in Flow Cytometry: Application to the Diagnosis of Hematologic Malignancy. // Blood, 1997, v.90, No. 18, 28632892.

39. Jia L., Macey M.G., Yin Y., Newland A.C., Kelsey S.M. / Subsellular distribution and redistribution of Bcl-2 family proteins in human leukemia cells undergoing apoptosis. // Blood, 1999, v.93, No.7,2353-2359.

40. Jurgensmeier J.M., Xie Z., Deveraux Q., Ellerby L., Bredesen D., Reed J.C. / Bax directly induces release of cytochrome с from isolated mitochondria. // Proc. Natl. Acad. Sci. USA, 1998, v.95,4997-5002.

41. Kara\vajew L., Wuchter C., Rupper V., Drexler H., Gruss H.-J., Dorken В., Ludwig W.-D. / Differential CD95 expression and function in T and В lineage acute lymphoblastic leukemia cells. // Leukemia, 1997, v.l 1, 1245-1252.

42. Kaufmann S.H., Karp J.E., Svingen P.A., Krajewski S., Burke P.J., Gore S.D., Reed J.C. / Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. // Blood, 1998, v.91, No.3, 991-1000.

43. Kluck R.M., Bossy-Wetzel E., Green D.R., Nevvmeyer D.D. / The release of cytochrome с from mitochondria: a primary site for Bcl-2 regulation of apoptosis. //Science, 1997, v.275, 1132-1136.

44. Knudson C.M., Johnson G.M., Lin Y., Korsmeyer S.J. / Bax Accelerates Tumorogenesis in p53-deficient Mice. // Cancer Research, 2001, v.61, 659-665.

45. Knudson C.M., Korsmeyer S.J. / Bcl-2 and Bax function independently to regulate cell death. // Nat Genet, 1997, v.16, No.4, 358-363.

46. Kohn K.W., Jackman J., O'Connor P.M. / Cell cycle control and cancer chemotherapy. //J Cell Biochem, 1994, v.54, No.4, 440-452.

47. Korsmeyer S.J. / Bcl-2: a repressor of lymphocyte death. // Immunol Today, 1992, v.13, 285-288.

48. Kroemer G. / The proto-oncogene Bcl-2 and its role in regulating apoptosis. // Nature Medicine, 1997, v.3, No.6, 614-620.

49. Lagresle C., Bella C., Daniel P.T., Krammer P.H., Defrance T. / Regulation of germinal center В cell differentiation. Role of the human APO-l/Fas (CD95) molecule. //J Immunol, 1995, v. 154, No.l 1, 5746-5756.

50. Lagresle C., Mondiere P., Bella C., Krammer P.H., Defrance T. / Concurrent engagement of CD40 and the antigen receptor protects naive and memory human В cells from APO-l/Fas-mediated apoptosis. // J Exp Med, 1996, v. 183, No.4, 1377-1388.

51. Landovvski Т.Н., Qu N., Buyuksal I., Painter J.S., Dalton W.S. / Mutations in the Fas antigen in patients with multiple myeloma. // Blood, 1997, v.90, No.l 1, 42664270.

52. LeBien T.W. / Fates of human B-cell precursors. // Blood, 2000, v.96, No.l, 9-23.

53. Levine A.J. / p53, the cellular gatekeeper for growth and division. // Cell, 1997, v.88, No.3, 323-331.

54. Linette G.P., Li Y., Roth K, Korsmeyer S.J. / Cross talk between cell death and cell cycle progression: Bcl-2 regulates NFAT-mediated activation. // Proc. Natl. Acad. Sci. USA, 1996, v.93, 9545-9552.

55. Liu Y.J., de Bouteiller O., Fugier-Vivier I. / Mechanisms of selection and differentiation in germinal centers. // Curr Opin Immunol, 1997, v.9, No.2, 256262.

56. Lo Coco F., Gaidano G., Louie D.C., Offit K., Chaganti R.S., Dalla-Favera R. / p53 mutations are associated with histologic transformation of follicular lymphoma. // Blood, 1992, v.80, No.8, 2289-2295.

57. Louie D.C., Offit K., Jaslow R., Parsa N.Z., Murty V.V., Schluger A., Chaganti R.S. / p53 overexpression as a marker of poor prognosis in mantle cell lymphomas with t(l 1 ;14)(ql3;q32). // Blood, 1995, v.86, No.8, 2892-2899.

58. Marchetti P., Decaudin D., Macho A., Zainzami N., Hirsch Т., Susin S.A., Kroemer G. / Redox regulation of apoptosis: impact of thiol oxidation status on mitochondrial function. // Eur J Immunol, 1997, v.27, 289-296.

59. Marks D.I., Kurz BAY., Link M.P., Ng E., Sinister J.J., Lauer S.J., Brodsky I., Haines D.S. / High incidence of potential p53 inactivation in poor outcome childhood acute lymphoblastic leukemia at diagnosis/ // Blood, 1996, v.87, No.3, 1155-1161.

60. Masdehors P., Merle-Beral H., Maloum K., Omura S., Magdelenat H., Delic J. / Deregulation of the ubiquitin system and p53 proteolysis modify the apoptotic response in B-CLL lymphocytes. // Blood, 2000; v.96, No.l, 269-274.

61. Maung Z.T., MacLean F.R., Reid M.M., Pearson A.D., Proctor S.J., Hamilton P.J., Hall A.G. / The relationship between bcl-2 expression and response to chemotherapy in acute leukaemia. // Br J Haematol, 1994, v.88, No.l, 105-109.

62. Mazel S., Burtrum D., Petrie H.T. / Regulation of cell division cycle progression by bcl-2 expression: a potential mechanism for inhibition of programmed cell death. // J Exp Med, 1996, v. 183, No.5,2219-2226.

63. McDonnell TJ, Korsmeyer SJ. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice. Blood 82: 1994, 1993

64. Meijerink J.P.P., Mensink E.J.B.M., Wang K., Sedlak T.W., Sloetjes A.W., de Witte Т., Waksman G., Korsmeyer S.J. / Hematopoietic malignancies demonstrate loss-of-function mutations of Bax. // Blood, 1998, v.91, No.8, 2991-2997.

65. Merino R., Ding L., Veis D.J., Korsmeyer S.J., Nunez G. / Developmental regulation of the Bcl-2 protein and susceptibility to cell death in В lymphocytes. // EMBOJ, 1994, v.13No.3, 683-691.

66. Minn A.J., Velez P., Schendel S.L., Liang H., Muchmore S.W., Fesik S.W., Fill M., Thompson C.B. / Bcl-x(L) forms an ion channel in synthetic lipid membranes. // Nature, 1997, v.385, No.6614, 353-357.

67. Miyashita Т., Krajevvski S., Krajewska M., Wang H.G., Lin H.K., Liebennann D.A., Hoffman В., Reed J.C. / Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. // Oncogene, 1994, v.9, No.6, 17991805.

68. Miyashita Т., Reed J.C. / Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. // Cell, 1995, v.80, No.2, 293-299.

69. Molica S., Mannella A., Crispino G., Dattilo A., Levato D. / Comparative flow cytometric evaluation of Bcl-2 oncoprotein in CD5+ and CD5" B-cell lymphoid chronic leukemias. // Haematologica, 1997, v.82, 555-559.

70. Muschen M., Re D., Jungnickel В., Diehl V., Rajewsky K., Kuppers R. / Somatic mutation of the CD95 gene in human В cells as a side-effect of the germinal center reaction. // J. Exp. Med., 2000, v. 192, No. 12, 1833-1839.

71. Nagata S. And Golstein P. The Fas death factor. Science 267, 1995, 1449-1456

72. Nguyen P.L., Harris N.L., Ritz J., Robertson M.J. / Expression of CD95 antigen and Bcl-2 protein in non-Hodgkin's lymphomas and Hodgkin's disease. // American Journal of Pathology, 1996, v. 148, 847-853.

73. O'Brien S., del Giglio A., Keating M. / Advances in the biology and treatment of B-cell chronic lymphocytic leukemia. // Blood, 1995, v.85, No.2, 307-318.

74. Ohashi S., Segawa K., Okamura S., Urano H., Kanamori S., Ishikawa H., Hara K., Hukutomi A., Shiral K., Maeda M. / A clinicopathologic study of gastric mucosa-associated lymphoid tissue lymphoma. // Cancer, 2000, v.88, No. 10, 2210-2219. 4

75. Ohta K., Iwai K., Kasahara Y., Taniguchi N., Krajewski S., Reed J.C., Miyawaki T. / Imuunoblot analysis of cellular expression of Bcl-2 family proteins,

76. Bcl-2, Bax, Bcl-X and Mcl-1, in human peripheral blood and lymphoid tissues. // International Immunology, 1995, v.7, No.l 1, 1817-1825.

77. Oltvai Z.N., Milliman C.L., Korsmeyer S.J. / Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. // Cell, 1993, v.74, No.4, 609-619.

78. O'Reillly L.A., Huang D.C.S., Strasser A. / The cell death inhibitorBcl-2 and its homologues influence control of cell cycle entry. // The EMBO Journal, 1996, v.15, No.24, 6976-6990.

79. Pines J. / Cell cycle. p21 inhibits cyclin shock. // Nature, 1994, v.369, No.6481, 520-521.

80. Plumas J., Jacob M.-C., Chaperot L., Molens J.-P., Sotto J.-J., Bensa J.-C. / Tumor В cells from Non-Hodgkin's lymphoma are resistant to CD95 (Fas/Apo-l)-mediated apoptosis. // Blood, 1998, v.91, No.8,2875-2885.

81. Reed J.C. (1)/ Cytochrome c: Can't Live with It Can't Live without It. // Cell, 1997, v.91, 559-562.

82. Reed J.C. (2)/ Double identity for proteins of the Bcl-2 family. // Nature, 1997, v.387, 773-776.

83. Reed J.C. / Mechanisms of apoptosis. // American Journal of Pathology, 2000, v.157, No.5, 1415-1430.

84. Renner S., Weisz J., Krajewski S., Krajevvska M., Reed J.C., Lochtenstein A. / Expression of BAX in plasma cell dyscrasias. // Clinical Cancer Research, 2000, v.6, No.6, 2371-2380.

85. Robertson L.E., Plunkett W., McConnell K., Keating M.J., McDonnell T.J. / Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. // Leukemia, 1996, v. 10, No.3, 456459.

86. Rosse Т., Oliver R., Monney L., Rager M., Conus S., Fellay I., Jansen В., Borner C. / Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c. // Nature, 1998, v.391, 496-499.

87. Sander C.A., Yano Т., Clark H.M., Harris C., Longo D.L., Jaffe E.S., Raffeld M. / p53 mutation is associated with progression in follicular lymphomas. // Blood, 1993, v.82, No.7, 1994-2004.

88. Sattler M. and Liang H. / Structure of bcl-XL-Bak peptide complex: Recognition between regulators of apoptosis. // Science, 1997, v.275, No.5302, 983-986.

89. Sedlak T.W., Oltvai Z.N., Yang E., Wang K., Boise L.H., Thompson C.B., Korsmeyer S.J. / Multiple Bcl-2 family members demonstrate selective dimerization with Bax. // Proc Natl Acad Sci USA, 1995, v.92, 7834-7838.

90. Simonian P.L., Grillot D.A.M., Andrews D.W., Leber В., Nunez G. / Bax hoinodimerization is not required for bax to accelerate chemotherapy-induced cell death. // The Journal of Biological Chemistry, 1996, v.271, No.50, 32073-32077.

91. Soussi T. / p53 antibodies in the sera of patients with vatious types of cancer: a review. // Cancer Research, 2000, v.60, 1777-1788.

92. Starostik P., Patzner J., Greiner A., Sclnvarz S., Kalla J., Ott G., Muller Herinelink H.K. / Gastric marginal zone B-cell lymphomas of MALT type develop along 2 distinct pathogenetic pathways. //Blood, 2002, v.99, No.l, 3-9.

93. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science, 1995,267: 1456

94. Thornberry N.A. and Lazebnik Y. / Caspases: Enemies within. // Science, 1998, v.281,1312-1316.

95. Vander Heiden M.G., Chandel N.S., Williamson E.K., Schumacker P.T., Thompson C.B. / Bcl-xL regulates the membrane potential and volume homeostasis of mitochondria. // Cell, 1997, v.91, No.5, 627-637.

96. Wada M., Bartram C.R., Nakamura H., Hackiya M., Chen D.-L., Borenstein J., Miller C.W., Ludwig L., Hansen-Hagge Т.Е., Ludwig W.D., Reiter A., Mizoguchi

97. H., Koeffler Н.Р. / Analysis of p53 mutations in a large series of lymphoid malignancies of childhood. // Blood, 1993, v.82, 3163.

98. Wattel E., Preudhomme C., Hecquet В., Vanmmbeke M., Quesnel В., Dervite1., Morel P., Fenaux P. / p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. // Blood, 1994, v.84,No.9, 3148-3157.

99. Wickremasinghe R.G., Hoffbrand A.V. / Biochemical and genetic control of apoptosis: relevance to normal hematopoiesis and hematological malignancies. // Blood, 1999, v.93, No.l 1, 3587-3600.

100. Willis T.G. and Dyer M.J.S. / The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies. // Blood, 2000, v.96, No.3, 808-822.

101. Wilson W.H., Teruya-Feldstein J., Fest Т., Harris C., Steinberg S.M., Jaffe E.S., Raffeld M. / Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in Non-Hodgkin's lymphomas. // Blood, 1997, v.89, No.2, 601609.

102. Wlodarska I., Pittaluga S., Hagemeijer A., De Wolf-Peeters C., Van Den Berghe H. / Secondary chromosome changes in mantle cell lymphoma. // Haematologica 1999; v.84, 594-599.

103. Wolter K.G., Hsu Y.-T., Smith C.L., Nechushtan A., Xi X.-G., Youle R.J. / Movement of Bax from the Cytosol to Mitochondria during Apoptosis. // The Journal of Cell Biology, 1997, v.139, No.5, 1281-1292.

104. Wu M., Bellas R.E., Shen J., Sonenshein G.E. / Roles of the tumor suppressor p53 and the cyclin-dependent kinase inhibitior p2lWAF1/CIP1 in receptor-mediatedapoptosis of WEHI 231 В Lymphoma cells. // J. Exp. Med., 1998, v. 187, No. 10, 1671-1679.

105. Yang E. and Korsmeyer S.J. / Molecular thanatopsis: a discourse on the Bcl2 family and cell death. // Blood, 1996, v.88, No.2,386-401.

106. Yang J., Liu X., Bhalla K., Kim C.N., Ibrado A.M., Cai J., Peng T.-I., Jones D.P., Wang X. / Prevention of apoptosis by Bcl-2: Release of cytochrome с from mitochondria blocked. // Science, 1997, v.275, 1129-1132.

107. Yang E., Zha J., Jockel J., Boise L.H., Thompson C.B., Korsmeyer S.J. / Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. //Cell, 1995, v.80, No.2, 285-291.

108. Zha H., Aime-Sempre C., Sato Т., Reed J.C. / Proapoptotic Protein Bax Heterodiinerizes with Bcl-2 and Homodimerizes with Bax via a Novel Domain (BH3) Distinct from BH1 and BH2. // The Journal of Biological Chemistry, 1996, v.271,No.l3, 7440-7444.

109. Zamzami N., Brenner C., Marzo I., Susin S.A., Kroemer G. / Subcellular and submitochondrial mode of action of Bcl-2-like oncoproteins. // Oncogene, 1998, v. 16, 2265-2282.

110. Zhivotovski В., Burgess D.H., Schlegel J., Porn I., Vanags D., Orrenius S. / Proteases in Fas-mediated apoptosis. // Journal of Cellular Biochemistry, 1997, v.64,43-49.

111. Zhivotovsky В., Orrenius S., Brustugun O.T., Doskeland S.O.// Injected cytochrome с induces apoptosis. // Nature, 1998, v.391, No.6666, 449-450.